Zusammengesetzter Bewertungsbereich · konservativ ¥34–¥36 / fair ¥45–¥55 / optimistisch ¥64–¥68. Bei ¥53.6, Innerhalb des fairen Bereichs des inneren Werts.
Bei Veröffentlichung ¥50.04 (26. Juni 2026)
NMPA approved cyclosporine eye drops IV, described by Hengrui as China’s first 0.1% anhydrous cyclosporine eye drop.
Possible impact:May affect expectations for the ophthalmology pipeline and non-oncology revenue mix.
NMPA approved a new perioperative NSCLC indication for Hengrui's adebrelimab injection.
Possible impact:May affect expectations for lung cancer immunotherapy sales and commercialization of Hengrui's innovative pipeline.
EMA accepted Hengrui's marketing authorization application for rezvilutamide, its first self-developed innovative drug filing in the EU.
Possible impact:May affect expectations for Hengrui's overseas strategy and prostate cancer drug opportunity in Europe.
NMPA approved dalpiciclib for adjuvant treatment of high-risk HR-positive, HER2-negative early breast cancer.
Possible impact:May affect expectations for the CDK4/6 franchise and breast cancer indication expansion.
By May 31, Hengrui had repurchased 12.06 million A-shares for about RMB 772 million under its buyback plan.
Possible impact:May affect views on equity incentive reserves, capital allocation, and management confidence.
Automatically summarized from public sources; for context only, not investment advice.
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.